Quarterly report pursuant to Section 13 or 15(d)

Investment in Viking Therapeutics, Inc. (Details)

v3.5.0.2
Investment in Viking Therapeutics, Inc. (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 13 Months Ended
Jan. 31, 2016
USD ($)
May 31, 2015
USD ($)
$ / shares
shares
May 31, 2014
USD ($)
program
Mar. 31, 2016
USD ($)
Mar. 31, 2015
USD ($)
May 31, 2015
$ / shares
Dec. 31, 2015
USD ($)
Schedule of Equity Method Investments [Line Items]              
Note receivable from Viking Therapeutics       $ 4,767     $ 4,782
Change in fair value of the convertible debt receivable from Viking       $ 15 $ 0    
Viking              
Schedule of Equity Method Investments [Line Items]              
Number of programs licensed | program     5        
Loss percentage recorded           100.00%  
Debt | Viking              
Schedule of Equity Method Investments [Line Items]              
Convertible loan facility     $ 2,500        
Viking Therapeutics, Inc.              
Schedule of Equity Method Investments [Line Items]              
Equity interest in outstanding common stock of Viking (percent)       49.40%      
Note receivable, stated interest rate (percent) 2.50%           5.00%
LSA, lock-up period extension 1 year            
Note receivable, amount due upon consummation of capital financing transaction $ 1,500            
Note receivable, cash due upon consummation of capital financing transaction $ 300            
Note receivable, repayment in equity (percent) 200.00%            
Common Stock              
Schedule of Equity Method Investments [Line Items]              
Aggregate value of shares received under licensing agreement   $ 29,200          
IPO shares purchased by the Company (shares) | shares   1.1          
Payments to acquire IPO shares   $ 9,000          
Common Stock | Viking Therapeutics, Inc. | IPO              
Schedule of Equity Method Investments [Line Items]              
Shares issued in IPO (shares) | shares   3.7          
IPO aggregate offering price   $ 29,200          
IPO share price (USD per share) | $ / shares   $ 8.00       $ 8.00